-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.AUD↓
Dir gefallen die Informationen zu Dimerix Limited?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Dimerix Limited?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Dimerix Limited?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Dimerix Limited?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
23 News & Informationen zur Dimerix Limited Aktie
Good timing, and flexible funding: Why Dimerix’s $20m share placement is ‘transformational’ for the business, with CEO Nina Webster
The placement gives Dimerix a flexible, long-term funding solution as the Phase 3 clinical trial kicks off with first ethics submission.
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August
Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs for ASX health stocks.
Weekly ASX small cap wrap: Local stocks look to get back on the horse as the Fed looms
The ASX got back in the saddle to some extent this week, after a mid-August iron ore price rout that flowed through to double-digit percentage falls for the big miners.
Dimerix shares up 8% on DMX-200 FSGS Phase 3 trial news
Dimerix has started the Phase 3 trial of its lead drug candidate DMX-200 in patients with rare kidney disease Focal Segmental Glomerulosclerosis (FSG).
ASX Health Stocks: Dimerix commences Phase 3 trial, while IDT scoots 10pc after restoring profit
ASX biotech stock Dimerix (ASX:DXB) announced that it has commenced ACTION3, a Phase III study in patients with focal segmental glomerulosclerosis (FSGS).
Dimerix (ASX:DXB) launches Phase 3 study in rare kidney disease
Dimerix (ASX:DXB) kicks off a Phase 3 clinical study in patients with a rare kidney disease.
Rise and Shine: What you need to know before the ASX opens
The copper supply crunch 'to end all supply crunches', uranium approaches 5-year highs, and can 'fake meat' become a $6bn ASX sector?
Closing Bell: Energy shares push ASX higher
Closing Bell: Energy shares push ASX higher
Hot Money Monday: BNPL gets the shivers, while Ikwezi Mining runs hot as coal makes a comeback
After two straight weeks where lithium stocks dominated the Running Hot list, this week's list was led by coal stock Ikwezi Mining (ASX:IKW).
ScoPo’s Powerplays: Quality names continue to catch a bid as earnings roll in
ASX Healthcare (XHJ) index finished the week up 2.23%, compared to the broader market which ended 2.20% lower. CSL and Cochlear reported earnings.
Weekly ASX small cap wrap: Iron ore pulls the market down after jumping off a cliff
Weekly ASX small cap wrap: Iron ore pulls the market down after jumping off a cliff
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress
Dimerix (ASX:DXB) eyes $20m for phase three trials
Dimerix (ASX:DXB) has received firm commitments to undertake a two-phase placement to raise $20 million.
Closing Bell: ASX gains over 0.5pc to reach new record high
Closing Bell: ASX gains over 0.5pc to reach new record high
ASX Capital Raise Roundup: Arise, Sir Lithium
The past several months, the biggest thematic in the market was simply no true direction, however, we have finally seen a truly hot sector… lithium!
Rise and Shine: What you need to know before the ASX opens
To the ASX, companies expected to report their annual earnings today include: Resmed (ASX:RMD), Incannex Healthcare (ASX:IHL), and 3P Learning (ASX:3PL).
Closing Bell: ASX edges higher as reporting season throws up plenty of winners
Closing Bell: ASX edges higher as reporting season throws up plenty of winners
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing
ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the benchmark rose by 3%.
Dimerix rounds out Q4 with a multi-channel product suite and key support from global regulators as clinical trials progress
Biopharmaceutical company Dimerix (ASX:DXB) makes significant operational advances in the quarter with global support of regulators.
Market Highlights and 5 ASX Small Caps to watch on Tuesday
ASX small caps to watch on Tuesday 27 July, and highlights from Wall Street overnight. ASX stocks include Japara (JHC), Dimerix (DXB), and MGC Pharma(MXC).
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down
V-Con: Talking medical innovations and breakthrough treatments with ASX biotechs
V-Con is Stockhead’s investing focused video conference series, bringing you expert insights, panel discussions and presentations from leading analysts,
Check Up: From Moderna’s effective jabs to Patrys’ brain cancer breakthrough
Stockhead reports ASX biotech and healthcare roundup for the last fortnight. Stocks include Actinogen (ACW), Suda Pharma (SUD), and Patrys (PAB).